title: Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol.
abstract: Tardive dyskinesia (TD) is relatively common among psychiatric patients on maintenance therapy with typical neuroleptics and persists in more than 20% even after withdrawal of the medication. Such persistence suggests an underlying pathology due to neurotoxicity. We present evidence for such a neurotoxic mechanism in a baboon model of TD. Four baboons were treated chronically with the dehydration product of haloperidol, 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine (HPTP), which is metabolized, similarly to haloperidol, to two neurotoxic pyridinium species. The animals developed orofacial dyskinesia which persisted after HPTP was ceased. Serial sections of the entire brain from the four treated animals and four vehicle-treated controls revealed volume loss in the basal forebrain and hypothalamus. Histological evaluation demonstrated a reduction in the density of magnocellular neurons in the anterior region of the nucleus basalis of Meynert (NbM). We speculate that the loss of these NbM neurons may be associated with the persistent orofacial dyskinesia observed in the HPTP-treated animals. These findings may contribute to a better understanding of neuroleptic-induced TD.
authors.affiliation: Prince of Wales Medical Research Institute, Randwick, NSW, Australia.
authors.forename: G M
authors.initials: GM
authors.lastname: Halliday
authors.forename: S M
authors.initials: SM
authors.lastname: Pond
authors.forename: H
authors.initials: H
authors.lastname: Cartwright
authors.forename: D A
authors.initials: DA
authors.lastname: McRitchie
authors.forename: N
authors.initials: N
authors.lastname: Castagnoli
authors.forename: C J
authors.initials: CJ
authors.lastname: Van der Schyf
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology* / Q000503:physiopathology; D005152:Facial Muscles / Q000503:physiopathology; D006220:Haloperidol / Q000009:adverse effects / Q000031:analogs & derivatives*; D007031:Hypothalamus / Q000187:drug effects* / Q000473:pathology; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D010215:Papio; D016548:Prosencephalon / Q000187:drug effects* / Q000473:pathology
chemical_list: D014150:Antipsychotic Agents; C101091:4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine; D006220:Haloperidol